FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311552362> ?p ?o ?g. }

• W4311552362 abstract "Abstract Background CAB+RPV LA is a complete regimen for treatment of virologically suppressed people with HIV (PWH). As an injectable therapeutic administered by a healthcare provider (HCP), CAB+RPV LA may alleviate challenges with adherence to daily oral therapy and reduce fear of HIV status disclosure with oral treatment. Real world perspectives from HCPs and PWH are needed to enable successful delivery of this treatment in US healthcare settings. Methods BEYOND is a 2 year prospective, observational, real-world study of utilization, outcomes, and experience of PWH initiating CAB+RPV LA across 30 US sites. HCPs at participating sites (treaters, injectors, drug acquisition/reimbursement staff) completed surveys at site activation (Sep 2021-Feb 2022; with follow-up surveys planned at 6, 12, 24 months) evaluating experiences to date with implementation of CAB+RPV LA at their sites. Results HCPs from 24 sites responded to the initial survey (Table 1). 75% of HCPs estimated that ≥25% of their PWH are eligible for CAB+RPV LA, and 71% of sites are proactively discussing the regimen with ≥25% of PWH. The majority (79%) of treaters reported they were extremely/very positive about administering CAB+RPV LA. Over 90% of injectors reported a positive overall opinion about administering CAB+RPV LA, and 86% reported the injections were easy to administer. Most (87%) HCPs reported injection visits taking ≤45 minutes, including waiting time. Over 95% of sites have patient reminder systems; 86% will manually identify missed injections and all reported manual follow up by site staff. All sites utilizing the injection education video on the external HCP website (n=15/15) found it helpful and 94% (n=16/17) utilizing reimbursement specialists found them to be helpful. In their experience to date, most clinics reported only needing to increase coordination with the pharmacy team and add injection training to implement CAB+RPV LA. The most frequently reported benefits of implementing CAB+RPV LA by HCPs included assurance of patient adherence and patient engagement in their HIV treatment (Table 2). Conclusion Early real-world data from US HCPs in this study indicates interest in and anticipated uptake of CAB+RPV LA at their sites, positive overall opinion, and multiple benefits of administering the CAB+RPV LA regimen to PWH. Disclosures Ricky K. Hsu, MD, Gilead: Honoraria|Merck: Honoraria|ViiV: Advisor/Consultant|ViiV: Grant/Research Support|ViiV: Honoraria John Phoenix, MSN, APRN, FNP-C, Gilead Sciences: Advisor/Consultant|Gilead Sciences: Honoraria|Gilead Sciences: speaker bureau, research funding|Janssen Pharmaceutical: Advisor/Consultant|Janssen Pharmaceutical: Honoraria|Lupin Pharmaceuticals: Advisor/Consultant|Lupin Pharmaceuticals: Honoraria|Napo pharmaceutical: Honoraria|Napo pharmaceutical: speaker bureau|Scinexis: Advisor/Consultant|Scinexis: Honoraria|ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Honoraria|ViiV Healthcare: speaker bureau, clinical research funding Gary I. Sinclair, MD, ABBVIE: Grant/Research Support|Gilead: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Janssen: Honoraria|Merck: Grant/Research Support|Thera: Grant/Research Support|Thera: Honoraria|ViiV/GSK: Advisor/Consultant|ViiV/GSK: Grant/Research Support|ViiV/GSK: Honoraria Samir K. Gupta, MD, Gilead Sciences: Advisor/Consultant|GSK/ViiV: Advisor/Consultant|GSK/ViiV: Grant/Research Support Ana Puga, MD, FAAP, AAHIVS, Care Resource: Healthcare provider (HCP)|ViiV Healthcare: Stocks/Bonds Kaitlin Nguyen, PharmD, AAHIVE, ViiV Healthcare: Stocks/Bonds Catherine K. Schubert, PharmD, ViiV Healthcare: Stocks/Bonds Deanna Merrill, PharmD, MBA, AAHIVP, ViiV Healthcare: Salaried employee|ViiV Healthcare: Stocks/Bonds David Richardson, BA, ViiV Healthcare: ViiV provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results. Kate Nelson, M.Ed, ViIV: ViiV provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results. Maria Reynolds, MStat, ViiV Healthcare: Viiv provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results. Laurie Zografos, BS, Viiv: ViiV provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results. Ashley Jean-Louis, MPH, ViiV Healthcare: (ViiV provided funding to RTI for the development of the study materials, the conduct of the study, and analysis & interpretation of study results.) Cindy Garris, MS, ViiV Healthcare: Employee|ViiV Healthcare: Stocks/Bonds." @default.
• W4311552362 created "2022-12-27" @default.
• W4311552362 creator A5005600970 @default.
• W4311552362 creator A5009434419 @default.
• W4311552362 creator A5009518467 @default.
• W4311552362 creator A5024706647 @default.
• W4311552362 creator A5026575562 @default.
• W4311552362 creator A5028839724 @default.
• W4311552362 creator A5029977496 @default.
• W4311552362 creator A5051457559 @default.
• W4311552362 creator A5061735676 @default.
• W4311552362 creator A5063050857 @default.
• W4311552362 creator A5072422918 @default.
• W4311552362 creator A5081237345 @default.
• W4311552362 creator A5086181050 @default.
• W4311552362 creator A5089611169 @default.
• W4311552362 date "2022-12-01" @default.
• W4311552362 modified "2023-10-14" @default.
• W4311552362 title "1288. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)" @default.
• W4311552362 doi "https://doi.org/10.1093/ofid/ofac492.1119" @default.
• W4311552362 hasPublicationYear "2022" @default.
• W4311552362 type Work @default.
• W4311552362 citedByCount "0" @default.
• W4311552362 crossrefType "journal-article" @default.
• W4311552362 hasAuthorship W4311552362A5005600970 @default.
• W4311552362 hasAuthorship W4311552362A5009434419 @default.
• W4311552362 hasAuthorship W4311552362A5009518467 @default.
• W4311552362 hasAuthorship W4311552362A5024706647 @default.
• W4311552362 hasAuthorship W4311552362A5026575562 @default.
• W4311552362 hasAuthorship W4311552362A5028839724 @default.
• W4311552362 hasAuthorship W4311552362A5029977496 @default.
• W4311552362 hasAuthorship W4311552362A5051457559 @default.
• W4311552362 hasAuthorship W4311552362A5061735676 @default.
• W4311552362 hasAuthorship W4311552362A5063050857 @default.
• W4311552362 hasAuthorship W4311552362A5072422918 @default.
• W4311552362 hasAuthorship W4311552362A5081237345 @default.
• W4311552362 hasAuthorship W4311552362A5086181050 @default.
• W4311552362 hasAuthorship W4311552362A5089611169 @default.
• W4311552362 hasBestOaLocation W43115523621 @default.
• W4311552362 hasConcept C126322002 @default.
• W4311552362 hasConcept C142462285 @default.
• W4311552362 hasConcept C160735492 @default.
• W4311552362 hasConcept C162324750 @default.
• W4311552362 hasConcept C23131810 @default.
• W4311552362 hasConcept C2778723075 @default.
• W4311552362 hasConcept C2779703844 @default.
• W4311552362 hasConcept C2781413609 @default.
• W4311552362 hasConcept C2993143319 @default.
• W4311552362 hasConcept C3013748606 @default.
• W4311552362 hasConcept C50522688 @default.
• W4311552362 hasConcept C512399662 @default.
• W4311552362 hasConcept C71924100 @default.
• W4311552362 hasConceptScore W4311552362C126322002 @default.
• W4311552362 hasConceptScore W4311552362C142462285 @default.
• W4311552362 hasConceptScore W4311552362C160735492 @default.
• W4311552362 hasConceptScore W4311552362C162324750 @default.
• W4311552362 hasConceptScore W4311552362C23131810 @default.
• W4311552362 hasConceptScore W4311552362C2778723075 @default.
• W4311552362 hasConceptScore W4311552362C2779703844 @default.
• W4311552362 hasConceptScore W4311552362C2781413609 @default.
• W4311552362 hasConceptScore W4311552362C2993143319 @default.
• W4311552362 hasConceptScore W4311552362C3013748606 @default.
• W4311552362 hasConceptScore W4311552362C50522688 @default.
• W4311552362 hasConceptScore W4311552362C512399662 @default.
• W4311552362 hasConceptScore W4311552362C71924100 @default.
• W4311552362 hasIssue "Supplement_2" @default.
• W4311552362 hasLocation W43115523621 @default.
• W4311552362 hasOpenAccess W4311552362 @default.
• W4311552362 hasPrimaryLocation W43115523621 @default.
• W4311552362 hasRelatedWork W2184686930 @default.
• W4311552362 hasRelatedWork W2765980456 @default.
• W4311552362 hasRelatedWork W2804705496 @default.
• W4311552362 hasRelatedWork W2899687620 @default.
• W4311552362 hasRelatedWork W2900399017 @default.
• W4311552362 hasRelatedWork W2976382042 @default.
• W4311552362 hasRelatedWork W3043617471 @default.
• W4311552362 hasRelatedWork W4200371441 @default.
• W4311552362 hasRelatedWork W4311335976 @default.
• W4311552362 hasRelatedWork W4319262891 @default.
• W4311552362 hasVolume "9" @default.
• W4311552362 isParatext "false" @default.
• W4311552362 isRetracted "false" @default.
• W4311552362 workType "article" @default.